EAGLE PHARMACEUTICALS, INC.: restructuring charge — Eagle Pharmaceuticals cuts workforce 36% in realignment plan; expects $3.5M cash charges

EAGLE PHARMACEUTICALS, INC.

Board approved Realignment Plan reducing workforce ~36%, affecting employees supporting Byfavo, Barhemsys, Ryanodex.
Estimated $3.5M cash charges: $3.1M severance/healthcare, $0.4M retention benefits; recorded in Q1 2024.
Plan substantially complete by end of Q1 2024; company to continue commercialization with reduced team plus oncology sales.
Also performing impairment analysis over certain long-lived assets and inventory; may record non-cash impairment charges.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

EAGLE PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $3.5 million in cash charges affecting commercialization of Byfavo, Barhemsys and Ryanodex (approximately 36%).

Type: restructuring
Charge: approximately $3.5 million in cash charges
Affected area: commercialization of Byfavo, Barhemsys and Ryanodex
Headcount: approximately 36%

Exact text from the filing

expenditures relating to the Realignment Plan will not be known until all related activities have been completed. The Company estimates that it will incur approximately $3.5 million in cash charges in connection with the Realignment Plan, consisting of (i) approximately $3.1 million in cash-based expenses related to employee severance payments and healthcare

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001104659-24-029090

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.